Dizal’s Zegfrovy challenges chemo dominance in rare EGFR lung cancer mutation
Zegfrovy Phase 3 results could redefine EGFR exon20ins lung cancer treatment. Discover what this means for frontline therapy and future care strategies.
Pharma & Biotech